Walmart v. DOJ
Case Number:
21-40157
Court:
Nature of Suit:
Companies
Government Agencies
Sectors & Industries:
-
December 22, 2021
5th Circ. Won't Revive Walmart's Opioid Suit Against Feds
The Fifth Circuit on Wednesday declined to resurrect Walmart's suit against the U.S. Department of Justice that sought a declaration that the retail giant's opioid prescription practices are legal, saying Walmart hasn't identified a DOJ action that allows the suit to overcome sovereign immunity.
-
November 22, 2021
DOJ-Walmart Opioid Battle Halted As High Court Reviews CSA
The U.S. Department of Justice's sweeping lawsuit contending that Walmart's 5,000 pharmacies "helped fuel a national crisis" of opioid abuse is being halted until the U.S. Supreme Court decides newly accepted cases involving the boundaries of Controlled Substances Act enforcement, a Delaware federal judge ruled.
-
November 02, 2021
Walmart Tells 5th Circ. Its Pharmacists Are Stuck Over Opioids
Walmart on Tuesday urged the Fifth Circuit to reverse the dismissal of its suit against the U.S. Department of Justice that had sought a declaration that its prescription opioid sales were lawful, saying the "sword of Damocles" hung over the retail giant and its pharmacists.
-
July 26, 2021
DOJ Fights Walmart's Opioid Challenge At 5th Circ.
The U.S. Department of Justice said Friday the Fifth Circuit should reject Walmart's bid to resurrect a suit where the retail giant sought a declaration that its prescription opioid sales are lawful, saying the case "was barred from its inception."
-
May 18, 2021
US Chamber Backs Walmart In 5th Circ. Opioid Challenge
A slew of organizations, including the U.S. Chamber of Commerce and the National Association of Chain Drug Stores, have filed amicus briefs backing Walmart's bid to get the Fifth Circuit to revive a suit seeking clarification that the retail giant's current opioid prescription practices are lawful.
-
May 11, 2021
Walmart Wants 5th Circ. To Revive Opioid Suit Against Feds
Walmart Inc. has asked the Fifth Circuit to resurrect its lawsuit against the U.S. Department of Justice in which the retail giant sought a declaration that its prescription opioid sales are lawful, arguing that pre-enforcement review is a standard route for entities looking to clarify the scope of the law without waiting to be sued.